In accordance with the recently published financial statements, CRISPR Therapeutics AG has a Current Valuation of 6.53 B. This is 54.54% lower than that of the Healthcare sector and 40.57% higher than that of the Biotechnology industry. The current valuation for all United States stocks is 60.72% higher than that of the company.